HRVATSKA UDRUGA LEUKEMIJA I LIMFOMI DONOSI PREPORUKE ZA LIJEČENJE OSOBA KOJE ŽIVE S KRONIČNOM MIJELOIČNOM LEUKEMIJOM (KML), NAJNOVIJEG DOKUMENTA IZDANOG OD STRANE CML ADVOCATES NETWORKA (CML AN), I TO NA HRVATSKOM JEZIKU

 

Patient-friendly summary of 2020 ELN Guidelines for CML

- Published by the CML Advocates Network -

The new "European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia" were published in March 2020 in the prestigious journal Leukemia.
 
In order to improve the information available to patients and support them to access these guidelines, we have developed once more a patient-friendly summary of recommendations for CML management based on the ELN Recommendations 2020.

The patient-friendly summary of the ELN 2020 Recommendations for CML is made available at this stage in 8 languages and more are coming. 

Download your language version in English, Spanish, Croatian, French, Polish, Romanian, Serbian or Arabic by clicking on the images below:

We welcome community translations by member organisations of CML Advocates Network under the provision that members have them co-validated by a local CML specialist with whom the member organisation regularly works. If you would like to help us making the summary available in your language, please, contact us at info@cmladvocates.net.
 
Acknowledgements

The 2020 summary is based on the article "European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia", published in the medical journal Leukemia Hochhaus, A., Baccarani, M., Silver, R.T. et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34, 966–984 (2020). https://doi.org/10.1038/s41375-020-0776-2
 
Full and final editorial content is wholly and entirely the responsibility of the 
CML Advocates Network, hosted by the Leukemia Patient Advocates Foundation. Project management, translation costs, and printing were funded through an unrestricted educational grant from Pfizer Inc. to the CML Advocates Network. CML Advocates Network is additionally a recipient of unrestricted funding from Pfizer (and other corporate life-sciences companies) for its CML Horizons Congress, Community Advisory Board and Patient Registry.
 
We would like to express our gratitude to all collaborators involved in the development of this patient-friendly summary 2020. Authorship and ownership of this document rest solely with the CML Advocates Network.